FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, namely to oncology, and concerns using opioids for treating patients suffering from persistent malignant tumour. That is ensured by administering drugs containing opioids able to inhibit malignant cell proliferation in the effective amounts.
EFFECT: using opioids for treating the patients suffering from persistent malignant tumour.
15 cl, 17 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NON-REPLICATING VIRUS-DERIVED PARTICLES AND USE THEREOF | 2013 |
|
RU2705556C2 |
| BIFUNCTIONAL COMPOSITIONS FOR CANCER TREATMENT | 2019 |
|
RU2764175C1 |
| RAPAMYCIN TARGET INHIBITOR IN MAMMALIAN CELLS, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2019 |
|
RU2768583C2 |
| COMBINED THERAPY PAC-1 | 2016 |
|
RU2720509C2 |
| PROCASPASE 3 ACTIVATION BY COMBINATION THERAPY | 2013 |
|
RU2659936C2 |
| ANTIBODY SELECTIVE TO RECEPTOR APOPTOSIS-INDUCING LIGAND AND ASSOCIATED WITH TUMOR NECROSIS FACTOR AND ITS USING | 2002 |
|
RU2313537C2 |
| METHODS FOR PERSONALIZED MEDICAL TESTING EX VIVO FOR HEMATOLOGICAL NEOPLASMS | 2010 |
|
RU2636614C2 |
| HUMAN T-LYMPHOBLASTIC LEUCEMIA A4 CELL LINE USEFUL IN SCREENING OF ANTITUMOR AGENTS | 2004 |
|
RU2267532C1 |
| COMPOSITION OF ALPHA-FETOPROTEIN AND APOPTOSIS INDUCTORS FOR CANCER TREATMENT | 2006 |
|
RU2438695C2 |
| USE OF PARASITES AND EXTRACELLULAR VESICLES DERIVED FROM PARASITES FOR TREATING MALIGNANT TUMOUR | 2020 |
|
RU2814990C2 |
